This company has been marked as potentially delisted and may not be actively trading. Talaris Therapeutics (TALS) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsDividendInsider TradesTrendsBuy This Stock TALS vs. PRME, IKT, PLX, IZTC, ZIVO, CRTX, CVM, JATT, FNCH, and CLDIShould you be buying Talaris Therapeutics stock or one of its competitors? The main competitors of Talaris Therapeutics include Prime Medicine (PRME), Inhibikase Therapeutics (IKT), Protalix BioTherapeutics (PLX), Invizyne Technologies (IZTC), ZIVO Bioscience (ZIVO), Cortexyme (CRTX), CEL-SCI (CVM), JATT Acquisition (JATT), Finch Therapeutics Group (FNCH), and Calidi Biotherapeutics (CLDI). These companies are all part of the "medical" sector. Talaris Therapeutics vs. Its Competitors Prime Medicine Inhibikase Therapeutics Protalix BioTherapeutics Invizyne Technologies ZIVO Bioscience Cortexyme CEL-SCI JATT Acquisition Finch Therapeutics Group Calidi Biotherapeutics Talaris Therapeutics (NASDAQ:TALS) and Prime Medicine (NYSE:PRME) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk. Do analysts prefer TALS or PRME? Prime Medicine has a consensus price target of $8.92, suggesting a potential upside of 151.17%. Given Prime Medicine's stronger consensus rating and higher probable upside, analysts plainly believe Prime Medicine is more favorable than Talaris Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Talaris Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Prime Medicine 0 Sell rating(s) 3 Hold rating(s) 4 Buy rating(s) 1 Strong Buy rating(s) 2.75 Does the media favor TALS or PRME? In the previous week, Prime Medicine had 5 more articles in the media than Talaris Therapeutics. MarketBeat recorded 5 mentions for Prime Medicine and 0 mentions for Talaris Therapeutics. Prime Medicine's average media sentiment score of 0.29 beat Talaris Therapeutics' score of 0.00 indicating that Prime Medicine is being referred to more favorably in the news media. Company Overall Sentiment Talaris Therapeutics Neutral Prime Medicine Neutral Is TALS or PRME more profitable? Talaris Therapeutics' return on equity of -39.93% beat Prime Medicine's return on equity.Company Net Margins Return on Equity Return on Assets Talaris TherapeuticsN/A -39.93% -37.37% Prime Medicine N/A -107.87%-74.97% Do institutionals & insiders have more ownership in TALS or PRME? 67.6% of Talaris Therapeutics shares are owned by institutional investors. Comparatively, 70.4% of Prime Medicine shares are owned by institutional investors. 16.5% of Talaris Therapeutics shares are owned by insiders. Comparatively, 22.7% of Prime Medicine shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. Which has preferable valuation and earnings, TALS or PRME? Talaris Therapeutics has higher earnings, but lower revenue than Prime Medicine. Talaris Therapeutics is trading at a lower price-to-earnings ratio than Prime Medicine, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioTalaris TherapeuticsN/AN/A-$73.89M-$1.79-13.02Prime Medicine$4.96M96.30-$198.13M-$1.56-2.28 Which has more volatility and risk, TALS or PRME? Talaris Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500. Comparatively, Prime Medicine has a beta of 2.39, meaning that its stock price is 139% more volatile than the S&P 500. SummaryPrime Medicine beats Talaris Therapeutics on 12 of the 15 factors compared between the two stocks. Get Talaris Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for TALS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding TALS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart TALS vs. The Competition Export to ExcelMetricTalaris TherapeuticsBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$996.83M$284.84M$5.76B$9.60BDividend YieldN/AN/A4.41%4.10%P/E Ratio-13.02N/A31.1026.04Price / SalesN/A563.89434.92103.40Price / CashN/A22.4437.7358.48Price / Book5.3810.439.536.61Net Income-$73.89M-$115.81M$3.26B$265.56M Talaris Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)TALSTalaris TherapeuticsN/A$23.31+1.1%N/A+58.4%$996.83MN/A-13.0284PRMEPrime Medicine2.8851 of 5 stars$3.81+10.1%$8.92+134.0%-14.3%$512.43M$4.96M-1.86234Gap UpIKTInhibikase Therapeutics1.7044 of 5 stars$1.71-2.3%$6.50+280.1%+35.0%$130.10MN/A-0.646PLXProtalix BioTherapeutics3.0434 of 5 stars$1.61-1.8%$15.00+831.7%+76.2%$128.17M$59.76M-12.38200News CoveragePositive NewsAnalyst RevisionGap UpIZTCInvizyne TechnologiesN/A$10.03+1.7%N/AN/A$103.16MN/A0.0029News CoverageZIVOZIVO Bioscience0.2702 of 5 stars$18.22+1.2%N/A+112.3%$69.55M$15.85K-3.7310News CoverageGap UpCRTXCortexymeN/A$1.83+14.4%N/A+151.2%$55.18MN/A-0.6255CVMCEL-SCI1.3618 of 5 stars$8.35+9.4%N/A-71.5%$52.51MN/A-17.4043Positive NewsJATTJATT AcquisitionN/A$1.47+4.3%N/A-43.8%$25.36MN/A0.003Gap UpHigh Trading VolumeFNCHFinch Therapeutics GroupN/A$12.15-0.8%N/A+19.7%$19.51MN/A-1.38190CLDICalidi Biotherapeutics0.7442 of 5 stars$5.86+10.8%N/A-89.9%$17.73MN/A0.0038News Coverage Related Companies and Tools Related Companies Prime Medicine Alternatives Inhibikase Therapeutics Alternatives Protalix BioTherapeutics Alternatives Invizyne Technologies Alternatives ZIVO Bioscience Alternatives Cortexyme Alternatives CEL-SCI Alternatives JATT Acquisition Alternatives Finch Therapeutics Group Alternatives Calidi Biotherapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:TALS) was last updated on 8/23/2025 by MarketBeat.com Staff From Our PartnersBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredOut of 18,347 Cryptocurrencies... This is the ONLY OneThe Single Most Undervalued DeFi Protocol You've Never Heard Of If there's one cryptocurrency you should b...Crypto 101 Media | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Talaris Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Talaris Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
MarketBeat All Access